Aleksandra Olkina1, Aleksei Karachun2, Sergey Bagnenko2, Alexey Belyaev2, Aleksei Petrov2. 1. N.N. Petrov National Medical Research Center of Oncology, 68 Leningradskaya Street, pos. Pesochniy, Saint-Petersburg, Russia. olkina.aleksandra@yandex.ru. 2. N.N. Petrov National Medical Research Center of Oncology, 68 Leningradskaya Street, pos. Pesochniy, Saint-Petersburg, Russia.
Abstract
BACKGROUND: There is still a lack of randomized trials assessing the clinical value of mechanical bowel preparation (MBP) and oral antibiotics (OA) before rectal surgery. Existing studies are inconsistent regarding OA. The aim of this study is to examine the role of MBP with or without OA (using Alfa Normix®) on postoperative complications in patients undergoing rectal resection for cancer. METHODS: We are conducting a prospective multicenter randomized controlled trial comparing MBP (Moviprep®) with OA (Alfa Normix®) versus MBP alone in patients undergoing elective rectal resection for cancer. Patients with rectal or rectosigmoid cancer are randomized in a 1:1 allocation ratio. The primary endpoint is incisional surgical site infection (SSI) assessed within 30 days after surgery. Secondary endpoints are anastomotic leakage (AL), organ/space SSI, other postoperative complications, intraoperative complications, operation time, bowel preparation quality, bowel preparation adherence. Intention-to-treat and per protocol analyses will be performed. CONCLUSIONS: The results of the REPCA trial will demonstrate whether MBP + OA is superior to MBP alone in rectal cancer surgery. This trial might influence current preoperative practice and improve postoperative outcomes.
BACKGROUND: There is still a lack of randomized trials assessing the clinical value of mechanical bowel preparation (MBP) and oral antibiotics (OA) before rectal surgery. Existing studies are inconsistent regarding OA. The aim of this study is to examine the role of MBP with or without OA (using Alfa Normix®) on postoperative complications in patients undergoing rectal resection for cancer. METHODS: We are conducting a prospective multicenter randomized controlled trial comparing MBP (Moviprep®) with OA (Alfa Normix®) versus MBP alone in patients undergoing elective rectal resection for cancer. Patients with rectal or rectosigmoid cancer are randomized in a 1:1 allocation ratio. The primary endpoint is incisional surgical site infection (SSI) assessed within 30 days after surgery. Secondary endpoints are anastomotic leakage (AL), organ/space SSI, other postoperative complications, intraoperative complications, operation time, bowel preparation quality, bowel preparation adherence. Intention-to-treat and per protocol analyses will be performed. CONCLUSIONS: The results of the REPCA trial will demonstrate whether MBP + OA is superior to MBP alone in rectal cancer surgery. This trial might influence current preoperative practice and improve postoperative outcomes.
Authors: U O Gustafsson; M J Scott; M Hubner; J Nygren; N Demartines; N Francis; T A Rockall; T M Young-Fadok; A G Hill; M Soop; H D de Boer; R D Urman; G J Chang; A Fichera; H Kessler; F Grass; E E Whang; W J Fawcett; F Carli; D N Lobo; K E Rollins; A Balfour; G Baldini; B Riedel; O Ljungqvist Journal: World J Surg Date: 2019-03 Impact factor: 3.352
Authors: Avo Artinyan; Sonia T Orcutt; Daniel A Anaya; Peter Richardson; G John Chen; David H Berger Journal: Ann Surg Date: 2015-03 Impact factor: 12.969
Authors: Silvia Salvans; Xavier Mayol; Sandra Alonso; Ramon Messeguer; Marta Pascual; Sergi Mojal; Luis Grande; Miguel Pera Journal: Ann Surg Date: 2014-11 Impact factor: 12.969
Authors: Lindsey M Zhang; Darryl Schuitevoerder; Michael G White; Susan Feldt; Pranav Krishnan; Neil Hyman; Benjamin D Shogan Journal: J Surg Oncol Date: 2021-07-26 Impact factor: 3.454